07/06/2026
Not proven, but absolutely worth studying..
The GLP-1 cancer story keeps getting more interesting.
These drugs started as diabetes medications. Then they transformed obesity treatment. Now researchers are asking a bigger question:
Could GLP-1 medications also reduce cancer risk, slow cancer progression, or even improve the effectiveness of cancer treatments?
A new Washington Post article highlights several studies presented at ASCO looking at GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro in cancer prevention, progression, and survival. https://www.washingtonpost.com/health/2026/06/03/science-around-glp-1-drugs-cancer-is-suddenly-getting-lot-more-interesting/
The numbers are worth paying attention to:
* More than 40 ASCO studies, abstracts, oral presentations, and posters examined GLP-1 drugs and cancer.
* Obesity is associated with 13 different cancers.
* A University of Pennsylvania study of more than 100,000 women found GLP-1 users were about 30% less likely to develop breast cancer.
* A breast cancer analysis of more than 137,000 patients found 5-year survival of nearly 96% in GLP-1 users, compared with about 90% in similar nonusers.
* A study of 10,225 patients across seven solid tumors found GLP-1 use was associated with lower progression to stage IV disease.
* The strongest metastatic-progression signals were seen in lung, breast, colorectal, and liver cancers, with risk reductions in the range of about 31% to 50%.
* In chronic pancreatitis, GLP-1 use was associated with a more than 50% lower risk of pancreatic cancer.
* One acute myeloid leukemia analysis found a 63% lower risk among GLP-1 users.
* In metastatic colorectal cancer patients receiving immunotherapy, GLP-1 use was associated with lower mortality at 3 years, 5 years, and beyond.
* In more than 25,000 patients with metastatic non-small cell lung cancer treated with targeted therapies called TKIs, GLP-1 users had 5-year survival of 63%, compared with 40% among nonusers.
* In one lung cancer subgroup treated with ALK inhibitors, survival was reported as 85% in GLP-1 users versus 48% in nonusers.
That is a lot of signal.
But it is not proof.
Most of these studies are observational. That means they can show associations, but they cannot prove that GLP-1 drugs prevent cancer or improve cancer survival.
There is also an important caution: randomized trial data so far have not clearly proven that GLP-1 drugs reduce cancer risk. Many of those trials were not designed to study cancer outcomes and had limited follow-up, but the distinction matters.
Another nuance: some studies compare GLP-1 drugs against insulin. Since insulin itself may have cancer-promoting biology in some settings, that comparison could make GLP-1s look more favorable. When GLP-1s are compared with metformin or SGLT2 inhibitors, the advantage may be smaller or may disappear.
So no, I would not call GLP-1s cancer-prevention drugs today.
And I would not recommend them specifically to treat cancer.
But I also would not ignore this signal.
The most interesting question is whether the benefits are simply from weight loss, or whether GLP-1 drugs are doing something deeper: improving insulin resistance, lowering inflammation, altering immune signaling, changing the tumor microenvironment, or possibly making immunotherapy and targeted therapy work better.
Cancer is not only a genetic disease.
It is also influenced by metabolism, inflammation, hormones, immune function, insulin resistance, visceral fat, and the environment around the tumor.
That may be the real lesson here.
GLP-1 drugs may end up being one of the most important metabolic therapies of our time.
Not proven cancer drugs.
But absolutely worth studying.
